To evaluate the efficacy of PTK-ZK on metastatic melanoma either as a single agent treatment
or in combination with standard chemotherapy according to RECIST criteria. Further to
evaluate the safety and tolerability of PTK-ZK in patients with metastatic melanoma either as
a single agent treatment or in combination with standard chemotherapy
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Michael Weichenthal University of Schleswig-Holstein